|
WO1993017682A1
(en)
|
1992-03-04 |
1993-09-16 |
Abbott Laboratories |
Angiotensin ii receptor antagonists
|
|
GB9421816D0
(en)
|
1994-10-29 |
1994-12-14 |
Smithkline Beecham Plc |
Novel compounds
|
|
JPH11500415A
(ja)
|
1994-12-22 |
1999-01-12 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
アテローム性動脈硬化症治療用置換アゼチジン−２−オン
|
|
CH690264A5
(fr)
|
1995-06-30 |
2000-06-30 |
Symphar Sa |
Dérivés aminophosphonates substitués, leur procédé de préparation et leur utilisation pour la préparation de compositions pharmaceutiques.
|
|
CA2225627A1
(en)
|
1995-07-01 |
1997-01-23 |
Deirdre Mary Bernadette Hickey |
Azetidinone derivatives for the treatment of atherosclerosis
|
|
JP2002515728A
(ja)
|
1995-09-29 |
2002-05-28 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
新規用途
|
|
JP2000505063A
(ja)
|
1995-12-08 |
2000-04-25 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
アテローム性動脈硬化症の治療のためのアゼチジノン化合物
|
|
EP0869943A1
(en)
|
1995-12-08 |
1998-10-14 |
Smithkline Beecham Plc |
Monocyclic beta-lactame derivatives for treatment of atherosclerosis
|
|
GB9608649D0
(en)
|
1996-04-26 |
1996-07-03 |
Smithkline Beecham Plc |
Novel compounds
|
|
IL126696A0
(en)
|
1996-04-26 |
1999-08-17 |
Smithkline Beecham Plc |
Azetidinone derivatives for the treatment of atherosclerosis
|
|
GB9626615D0
(en)
|
1996-12-20 |
1997-02-05 |
Symphar Sa |
Novel compounds
|
|
GB9626536D0
(en)
|
1996-12-20 |
1997-02-05 |
Symphar Sa |
Novel compounds
|
|
GB9626616D0
(en)
|
1996-12-20 |
1997-02-05 |
Symphar Sa |
Novel compounds
|
|
JP2001522844A
(ja)
|
1997-11-06 |
2001-11-20 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
ピリミジノン化合物およびそれを含有する医薬組成物
|
|
JP2002523402A
(ja)
|
1998-08-21 |
2002-07-30 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
アテローム性動脈硬化症の治療用ピリミジノン
|
|
GB9910079D0
(en)
|
1999-05-01 |
1999-06-30 |
Smithkline Beecham Plc |
Novel compounds
|
|
CZ20013904A3
(cs)
|
1999-05-01 |
2002-04-17 |
Smithkline Beecham Plc |
Pyrimidinonové sloučeniny
|
|
GB9910378D0
(en)
|
1999-05-05 |
1999-06-30 |
Smithkline Beecham Plc |
Novel compounds
|
|
JP3757703B2
(ja)
|
1999-09-22 |
2006-03-22 |
凸版印刷株式会社 |
再封可能な開口維持部材付パウチ
|
|
HU229479B1
(en)
|
2000-02-16 |
2014-01-28 |
Glaxo Group Ltd |
Pyrimidine-4-one derivatives
|
|
GB0024807D0
(en)
|
2000-10-10 |
2000-11-22 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB0024808D0
(en)
|
2000-10-10 |
2000-11-22 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB0119793D0
(en)
|
2001-08-14 |
2001-10-03 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB0119795D0
(en)
|
2001-08-14 |
2001-10-03 |
Smithkline Beecham Plc |
Novel process
|
|
GB0127143D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Novel compounds
|
|
GB0127140D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Novel compounds
|
|
GB0127139D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Novel compounds
|
|
GB0127141D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham Plc |
Novel compounds
|
|
GB0208279D0
(en)
*
|
2002-04-10 |
2002-05-22 |
Glaxo Group Ltd |
Novel compounds
|
|
GB0208280D0
(en)
|
2002-04-10 |
2002-05-22 |
Glaxo Group Ltd |
Novel compounds
|
|
WO2004031145A2
(en)
|
2002-10-02 |
2004-04-15 |
Bristol-Myers Squibb Company |
Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
|
|
KR101122782B1
(ko)
|
2002-10-04 |
2012-04-12 |
프라나 바이오테크놀로지 리미티드 |
신경 활성 화합물
|
|
EP1644353A1
(de)
|
2003-07-02 |
2006-04-12 |
Bayer HealthCare AG |
Amid-substituierte 1, 2, 4-triazin-5 (2h) - one zur behandlung von chronisch inflammatorischen krankheiten
|
|
DE102004061009A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
Substituierte 1,2,4-Triazin-5(2H)-one
|
|
DE102004061008A1
(de)
|
2004-12-18 |
2006-06-22 |
Bayer Healthcare Ag |
3-Arylalkyl- und 3-Heteroarylalkyl-substituierte 1,2,4-Triazin-5(2H)-one
|
|
WO2008048867A2
(en)
*
|
2006-10-13 |
2008-04-24 |
Glaxo Group Limited |
Bicyclic heteroaromatic compounds
|
|
US20080090851A1
(en)
|
2006-10-13 |
2008-04-17 |
Colin Andrew Leach |
Bicyclic Heteroaromatic Compounds
|
|
US7705005B2
(en)
|
2006-10-13 |
2010-04-27 |
Glaxo Group Limited |
Bicyclic heteroaromatic compounds
|
|
US20080090852A1
(en)
|
2006-10-13 |
2008-04-17 |
Colin Andrew Leach |
Bicyclic Heteroaromatic Compounds
|
|
US8962633B2
(en)
|
2007-05-11 |
2015-02-24 |
Thomas Jefferson University |
Methods of treatment and prevention of metabolic bone diseases and disorders
|
|
WO2008141176A1
(en)
|
2007-05-11 |
2008-11-20 |
The Trustees Of The University Of Pennsylvania |
Methods of treatment of skin ulcers
|
|
US20080279846A1
(en)
|
2007-05-11 |
2008-11-13 |
Thomas Jefferson University |
Methods of treatment and prevention of neurodegenerative diseases and disorders
|
|
WO2009146034A2
(en)
|
2008-03-31 |
2009-12-03 |
Takeda Pharmaceutical Company Limited |
Mapk/erk kinase inhibitors and methods of use thereof
|
|
CA2781888C
(en)
|
2009-12-11 |
2019-06-18 |
Nono Inc. |
Agents and methods for treating ischemic and other diseases
|
|
EA023796B1
(ru)
*
|
2010-12-06 |
2016-07-29 |
Глэксо Груп Лимитед |
ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
|
|
EP2651403B1
(en)
|
2010-12-17 |
2020-12-02 |
Glaxo Group Limited |
Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
|
|
EP2736908A1
(en)
*
|
2011-07-27 |
2014-06-04 |
Glaxo Group Limited |
Bicyclic pyrimidone compounds
|